OMRON HEALTHCARE UNVEILS LONG-TERM CORPORATE VISION

KUALA LUMPUR, May 10 (Bernama) -- In March 2022, OMRON Group announced a new long-term vision, ‘Shaping the Future 2030’ (SF2030).

In its commitment to achieving this vision for the healthcare business domain, OMRON Healthcare Co Ltd (the Company), has established a long-term vision, ‘Going for ZERO, Preventive Care for the Health of Society’ and promises to develop new devices and services to meet the expectations of consumers, healthcare professionals and society at large.

By leveraging the sensing technologies and valuable insights developed in medical fields up to now, the Company will be focusing on the development of solutions for: cardiovascular diseases; respiratory diseases; and pain management.

Focus and commitment to these efforts will allow the Company to realise the long-term vision, according to a statement.

Firstly, Cardiovascular business: Zero cerebrovascular and cardiovascular events. Since the release of the first blood pressure monitor in 1973, the Company has always been focusing on developing easy-to-use and accurate blood pressure monitors as well as conducting educational activities for promoting blood pressure monitoring at home.

To accomplish the business vision of the cardiovascular domain, the Company will expand the target fields from monitoring cardiac dysfunction for the early detection, to the development of an upper-arm blood pressure monitor with built-in ECG technology, and the global launch of ECG analysis service.

Secondly, Respiratory business: Zero aggravation of respiratory diseases. Respiratory business will expand target diseases by adding COPD to the former asthma target.

The Company will distribute devices to support treatments and diagnosis in emerging nations lacking fully established medical systems. And for general households, especially in developed countries, the Company will be promoting symptom control and care services to alleviate soaring medical expenditures to relieve the burden of patients and their families.

Thirdly, Pain management: Zero restrictions on daily activities due to chronic pain. Within the pain management domain, the Company will focus on the development of devices incorporating new transcutaneous electrical nerve stimulation (TENS) technology, as well as providing an exercise therapy support service.

To accomplish the new vision of ‘Going for ZERO, Preventive Care for the Health of Society’, the Company aims to be indispensable within the chronic disease prevention and treatment fields, and then tries to challenge itself to provide society with solutions.

More details at https://healthcare.omron.com/

-- BERNAMA